412 related articles for article (PubMed ID: 36773075)
1. Treatment escalation and de-escalation decisions in Crohn's disease: Delphi consensus recommendations from Japan, 2021.
Nakase H; Esaki M; Hirai F; Kobayashi T; Matsuoka K; Matsuura M; Naganuma M; Saruta M; Tsuchiya K; Uchino M; Watanabe K; Hisamatsu T;
J Gastroenterol; 2023 Apr; 58(4):313-345. PubMed ID: 36773075
[TBL] [Abstract][Full Text] [Related]
2. Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus.
Steinhart AH; Panaccione R; Targownik L; Bressler B; Khanna R; Marshall JK; Afif W; Bernstein CN; Bitton A; Borgaonkar M; Chauhan U; Halloran B; Jones J; Kennedy E; Leontiadis GI; Loftus EV; Meddings J; Moayyedi P; Murthy S; Plamondon S; Rosenfeld G; Schwartz D; Seow CH; Williams C
Inflamm Bowel Dis; 2019 Jan; 25(1):1-13. PubMed ID: 30099529
[TBL] [Abstract][Full Text] [Related]
3. Anoperineal lesions in Crohn's disease: French recommendations for clinical practice.
Bouchard D; Abramowitz L; Bouguen G; Brochard C; Dabadie A; de Parades V; Eléouet-Kaplan M; Fathallah N; Faucheron JL; Maggiori L; Panis Y; Pigot F; Rouméguère P; Sénéjoux A; Siproudhis L; Staumont G; Suduca JM; Vinson-Bonnet B; Zeitoun JD
Tech Coloproctol; 2017 Sep; 21(9):683-691. PubMed ID: 28929282
[TBL] [Abstract][Full Text] [Related]
4. Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus.
Steinhart AH; Panaccione R; Targownik L; Bressler B; Khanna R; Marshall JK; Afif W; Bernstein CN; Bitton A; Borgaonkar M; Chauhan U; Halloran B; Jones J; Kennedy E; Leontiadis GI; Loftus EV; Meddings J; Moayyedi P; Murthy S; Plamondon S; Rosenfeld G; Schwartz D; Seow CH; Williams C
J Can Assoc Gastroenterol; 2018 Dec; 1(4):141-154. PubMed ID: 31799497
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
6. Use of Endoscopic Ultrasound to Guide Adalimumab Treatment in Perianal Crohn's Disease Results in Faster Fistula Healing.
Wiese DM; Beaulieu D; Slaughter JC; Horst S; Wagnon J; Duley C; Annis K; Nohl A; Herline A; Muldoon R; Geiger T; Wise PE; Schwartz DA
Inflamm Bowel Dis; 2015 Jul; 21(7):1594-9. PubMed ID: 25985245
[TBL] [Abstract][Full Text] [Related]
7. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients.
Strik AS; Löwenberg M; Buskens CJ; B Gecse K; I Ponsioen C; Bemelman WA; D'Haens GR
Scand J Gastroenterol; 2019 Apr; 54(4):453-458. PubMed ID: 31032686
[No Abstract] [Full Text] [Related]
8. Remicade does not abolish the need for surgery in fistulizing Crohn's disease.
Poritz LS; Rowe WA; Koltun WA
Dis Colon Rectum; 2002 Jun; 45(6):771-5. PubMed ID: 12072629
[TBL] [Abstract][Full Text] [Related]
9. Fibrosis and MAGNIFI-CD Activity Index at Magnetic Resonance Imaging to Predict Treatment Outcome in Perianal Fistulizing Crohn's Disease Patients.
van Rijn KL; Meima-van Praag EM; Bossuyt PM; D'Haens GR; Gecse KB; Horsthuis K; Snijder HJ; Tielbeek JAW; Buskens CJ; Stoker J
J Crohns Colitis; 2022 Jun; 16(5):708-716. PubMed ID: 34644395
[TBL] [Abstract][Full Text] [Related]
10. Cannabis for the treatment of Crohn's disease.
Kafil TS; Nguyen TM; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012853. PubMed ID: 30407616
[TBL] [Abstract][Full Text] [Related]
11. Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial.
Meima-van Praag EM; van Rijn KL; Wasmann KATGM; Snijder HJ; Stoker J; D'Haens GR; Gecse KB; Gerhards MF; Jansen JM; Dijkgraaf MGW; van der Bilt JDW; Mundt MW; Spinelli A; Danese S; Bemelman WA; Buskens CJ
Lancet Gastroenterol Hepatol; 2022 Jul; 7(7):617-626. PubMed ID: 35427495
[TBL] [Abstract][Full Text] [Related]
12. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Gordon M; Taylor K; Akobeng AK; Thomas AG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and treatment of perianal fistulising Crohn's disease in Colombia: Results of a multicentric registry.
Juliao-Baños F; Osorio L; Carvajal J; Mosquera-Klinger G; Medellín A; Padrón J; de Molano B; Puentes F; Muñoz E; Reyes G; Gil F; Parra-Izquierdo V; Sánchez H
Gastroenterol Hepatol; 2022 Nov; 45(9):690-696. PubMed ID: 35278506
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn's Disease.
Zhu M; Xu X; Feng Q; Cui Z; Wang T; Yan Y; Ran Z
Dig Dis Sci; 2021 May; 66(5):1658-1668. PubMed ID: 32524415
[TBL] [Abstract][Full Text] [Related]
15. Stem Cell Therapy for the Treatment of Crohn's Disease; Current Obstacles and Future Hopes.
El-Nakeep S
Curr Stem Cell Res Ther; 2022; 17(8):727-733. PubMed ID: 34514993
[TBL] [Abstract][Full Text] [Related]
16. INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial.
Panés J; Bouma G; Ferrante M; Kucharzik T; Nachury M; de la Portilla de Juan F; Reinisch W; Selvaggi F; Tschmelitsch J; Brett NR; Ladouceur M; Binek M; Hantsbarger G; Campbell-Hill S; Karki C; Buskens C
Inflamm Bowel Dis; 2022 Nov; 28(11):1737-1745. PubMed ID: 35099555
[TBL] [Abstract][Full Text] [Related]
17. Standardization of mesenchymal stromal cell therapy for perianal fistulizing Crohn's disease.
Molendijk I; van der Meulen-de Jong AE; Verspaget HW; Veenendaal RA; Hommes DW; Bonsing BA; Peeters KCMJ
Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1148-1154. PubMed ID: 30095479
[TBL] [Abstract][Full Text] [Related]
18. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy.
Papamichael K; Cheifetz AS
World J Gastroenterol; 2017 Sep; 23(34):6197-6200. PubMed ID: 28974885
[TBL] [Abstract][Full Text] [Related]
19. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease.
; Ma C; Hanzel J; Panaccione R; Sandborn WJ; D'Haens GR; Ahuja V; Atreya R; Bernstein CN; Bossuyt P; Bressler B; Bryant RV; Cohen B; Colombel JF; Danese S; Dignass A; Dubinsky MC; Fleshner PR; Gearry RB; Hanauer SB; Hart A; Kotze PG; Kucharzik T; Lakatos PL; Leong RW; Magro F; Panés J; Peyrin-Biroulet L; Ran Z; Regueiro M; Singh S; Spinelli A; Steinhart AH; Travis SP; van der Woude CJ; Yacyshyn B; Yamamoto T; Allez M; Bemelman WA; Lightner AL; Louis E; Rubin DT; Scherl EJ; Siegel CA; Silverberg MS; Vermeire S; Parker CE; McFarlane SC; Guizzetti L; Smith MI; Vande Casteele N; Feagan BG; Jairath V
Gastroenterology; 2022 Oct; 163(4):950-964. PubMed ID: 35788348
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice.
Knyazev OV; Kagramanova AV; Lishchinskaya AA; Samsonova NG; Orlova NV; Rogozina VA; Parfenov AI
Ter Arkh; 2018 Jun; 90(6):74-80. PubMed ID: 30701908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
